Innoquest Pathology - Healthcare Outlook - issue 1

A D I AG N O S I S O F

SUCCESS

Leading laboratory services across Malaysia, we dive into Innoquest Pathology Sdn Bhd, and speak to CEO Dr. Nelson Nheu about delivering high-quality and affordable diagnostics services throughout the country Writer: Marcus Kääpä | Project Manager: Callam Waller 2 | Healthcare Outlook Issue 1

INNOQUEST PATHOLOGY SDN BHD ASIA PACIFIC

Healthcare is a passion, born from the joy of helping other people.”

The words of Dr. Nelson Nheu, CEO at Innoquest Pathology Sdn Bhd (Innoquest) sum up the positive, people-centric spirit of a company working for the health and wellbeing

of people across Malaysia.

Formerly known as Gribbles Pathology, Innoquest is currently the largest private provider of diagnostic laboratory services in the country. This industry-leading position has been achieved by way of the company’s mission, to deliver affordable

diagnostics services of the highest quality, which is in turn made up of a multi-faceted mantra.

“We are medically managed, run under the stewardship of medical doctors; we are the lab of the future - investing in new technologies and tests that are clinically relevant, Healthcare Outlook Issue 1 | 3

INNOQUEST PATHOLOGY SDN BHD ASIA PACIFIC

NeoScience Always With You Our team, which we refer to fondly as the “One Together” team, lives by the principle of “Always with you”.

This symbolises our commitment to serve and support our clients from our hearts. We will continue to be the best version of ourselves and our ultimate pride lies in our clients’ success.

We aspire to be the preferred and referred partner for our clients through our exceptional ability in mastering the sciences and technologies behind Molecular Diagnostics, Clinical Diagnostics, Life Science and Big Biodata Management.

Company video

“WE ARE THE LAB OF THE FUTURE” – D R . N E L S O N N H E U , C E O , I N N O Q U E S T P AT H O L O G Y S D N B H D

and we create memorable patient experiences - from blood taking to releasing the report to a doctor, every patient’s journey is what matters to us,” Dr. Nheu tells us proudly.

For over 26 years, Gribbles Pathology has been the market leader in in-vitro diagnostics (IVD) in Malaysia. The rebranding in June 2022 comes with the backing of TPG as the company’s key investor, and more importantly with the leadership of PAH (Pathology Asia Holdings).

MALAYSIA’S MEDICAL SERVICE PAH is the fastest growing clinical lab in Southeast Asia (SEA), with a strong presence in Singapore, Malaysia, the Philippines, Vietnam and Australia. Innoquest’s regional reach and unparalleled volume allow the company to provide the highest quality at affordable prices.

Innoquest Malaysia obtained CAP (College of American Pathologists) accreditation and launched a powerful online platform that allows 4 | Healthcare Outlook Issue 1

company services to be delivered in a much more seamless and efficient way. Innoquest’s immediate plans are to have new features on this platform that will continue to improve the way that doctors can deliver lab test services to patients.

“Today we are operating through 75 sites across East and West Malaysia, offering employment to 1,100 staff in Malaysia,” Dr. Nheu says. “We have a very strong team of experts serving millions of patients each year, from couriers on their motorbikes who service thousands of clinics each day, rain or shine, to the dedicated scientists who provide potentially lifesaving test results around the clock.

“Our multidisciplinary services are the most comprehensive in Malaysia, covering the most special tests in genomics, anatomical pathology and adjuvant oncology molecular testing, down to the high volume and fully automated Biochemistry, Haematology, Immunology and Toxicology departments. If there is

Neoscience has established ourselves as one of the industry leaders through multiple national government awards and national collaboration projects.

We are blessed with the continuous support from our clients and partners.

Growing together with them and creating a self duplicating business model will always remain as our key drivers, with the aim to be the best of both worlds.

www.neoscience.com.my

Your Life Partner in Science “Neo” akin to New, Advance, and State-of-the-art, Innovative “Science” akin to competency in a particular branch of knowledge

Neoscience was established in 2012 with the vision of empowering medical diagnostics and life science research in Malaysia through the application of advanced technologies.

We are partnering with world-class, reputable suppliers who are reliable and provide innovative solutions to meet our clients’ needs in our current fast moving, ever-changing Medical and Life Science field.

We are confident and proud of every products and services that we provide; and our number one priority had always been to achieve a world-class customer experience and satisfaction.

Partnership with:

Our Solutions: POCT Diagnostic Immuno Diagnostic Molecular Diagnostic Life Science Research Labware & Consumables Molecular Lab Services Research Collaboration Next-Generation Sequencing

info@neoscience.com.my | www.neoscience.com.my | +603 7610 0388

INNOQUEST PATHOLOGY SDN BHD ASIA PACIFIC

any clinical lab service that we don’t provide in-house, we are able to refer these special testing services to the best international labs such as Mayo Clinic Laboratories, for which we are an exclusive distributor.”

With its regional strength, PAH is also able to acquire best-in-class laboratories with niche competencies, such as toxicology testing - until now, all confirmatory toxicology tests in Malaysia were serviced by the overwhelmed public sector.

DIAGNOSING THE INDUSTRY The recent COVID-19 pandemic has changed perceptions on the importance of healthcare and diagnostics in general, which echoes throughout Innoquest.

“For the first time in my lifetime, we have experienced how healthcare dictates our economy,” Dr. Nheu elaborates. “We saw how significantly the results of PCR testing determine

when and how the workforce can function, borders can be reopened for travel, or when we can board a train or even grab a taxi. All these basic things that we take for granted, have been limited to one single swab test result.”

The pandemic also accelerated the digitisation of the healthcare industry. With Innoquest and PAH’s vision of being innovative, and with recent investments and acquisitions to move the company ahead in this trend, there remains a lot of potential moving forward.

“I am very excited about the future of our company and that of the industry. I always believe that disruptive technology to our industry should be coming from within, allowing the experts to determine and shape the future of diagnostics and patient data management,” Dr. Nheu explains.

“Three years ago today, I would have not imagined that the diagnostics

HEALTHCARE OUTLOOK: WHY DID YOU ENTER THE MEDICAL DIAGNOSTICS SPACE? DR. NELSON NHEU, CEO: “My six years of medical residency in Australia were spent evenly between the public and private hospital system. No matter where my training was, or under which clinical speciality, one thing became clear to me: the importance of diagnostic tools in patient management. And unlike medical practice, IVD has the ability to scale massively.

“Today, more than 70 percent of medical decisions are based on laboratory test results. While in Malaysia the barrier to entry in this industry is relatively low,

BD About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.

The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers.

BD has 75,000 employees and a presence in virtually every country around the world to address some of the most challenging global health issues.

BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

bd.com

ABBOTT Abbott creates breakthrough products – in diagnostics, medical devices, nutrition and branded generic pharmaceuticals – that help you, your family and your community lead healthier lives.

For more than 130 years, we’ve put science and innovation to work – to create more possibilities for more people through the power of health.

Our purpose is to make the world a better place by bringing life-changing health technologies to the people who need them. That’s our commitment to helping you live your best life.

you need to be of significant scale in order to offer high-quality service at an affordable cost to the patient. Being the laboratory with the highest volume in this region and in Malaysia, it allows us to offer special tests that others aren’t able to, it allows us to be the referral lab for most hospitals and clinics, and it allows us to set up new tests with novel platforms that come at high initial cost.

“These are the main reasons I became interested in healthcare, diagnostics in particular, and in working with PAH in Malaysia under the Innoquest brand.”

6 | Healthcare Outlook Issue 1

www.abbott.com

INNOQUEST PATHOLOGY SDN BHD ASIA PACIFIC

LIFE-CHANGING TECHNOLOGY UNLOCKING POTENTIAL, TRANSFORMING THE FUTURE Abbott has driven innovation across medical diagnostics, pioneering new technologies and solutions that transform the way patients and healthcare providers receive accurate and timely results for diseases such as cancers, infectious disease, cardiovascular and more. We are creating the future of health and technology to change life for the better.

www.abbott.com

© 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. AMD.16498 APC 09/22

Healthcare Outlook Issue 1 | 7

INNOQUEST PATHOLOGY SDN BHD ASIA PACIFIC

industry would be what it is now. In my recent visit to the AACC Annual Scientific Meeting and Clinical Lab Expo Conference held in Chicago (US), the largest of its kind, it was clear to me how much emphasis is given to COVID-19-related testing, resulting in non-COVID-related tests taking a backseat.

“I am certain that this will quickly fall into balance again, but it was pleasing to see the willingness to invest in and rapidly adopt new technologies in IVD service delivery. This trend will only continue - and it is exciting to just imagine what this industry will look like in another three years.”

While Innoquest operates in a very traditional industry with a heavy focus on ‘standards of procedures’ and quality of care, emphasis is also being placed on innovating the ways it delivers its services. Nowadays, most things are at people’s fingertips and the traditional way of operating is not able to keep up with this trend. Thus, it is important for Innoquest, as the largest diagnostic healthcare provider

Hematology Laboratory: “Our staff go through stringent training in multiple disciplines… and our work culture focuses on teamwork and empathy towards patients and staff alike.”

8 | Healthcare Outlook Issue 1

“ H E A LT H C A R E I S A P A S S I O N , B O R N F R O M T H E J OY O F H E L P I N G OT H E R P E O P L E ” – D R . N E L S O N N H E U , C E O , I N N O Q U E S T P AT H O L O G Y S D N B H D

in Malaysia, to continuously innovate the way it delivers its services.

“Innoquest is in the best position to drive the future of the healthcare industry in Malaysia,” Dr. Nheu says.

“I firmly believe that “disruption” should be fostered from within. Much of our effort and passion is towards new methods of delivering our services, to ensure that the future of diagnostics never compromises on the fundamental ethics of healthcare.”

GROWTH SECTORS As the economy returns to normalcy, it is expected that there will be a rise in some areas of medicine which were put off during the pandemic period. Cancer diagnosis, elective procedures, non-communicable disease management, and flu outbreaks among others will see a

marked increase in hospital and clinic presentations.

The Innoquest team, already with the largest capacity, will continue to build-up to meet industry needs and to ensure that service levels are maintained, along with the company’s quest for continuous improvement.

According to Dr. Nheu, healthcare is not spared from the critical labour shortages seen in other industries. As hospitals and other health services experience the flood of increased workload, labour supply is a key constraint.

“We will continue to emphasise our human policies that have worked well for us, with extremely low staff turnover in our supervisors, management and above,” he elaborates further. “We also foresee that other areas of growth will

INNOQUEST PATHOLOGY SDN BHD ASIA PACIFIC

DEVELOPING MALAYSIAN HEALTHCARE Innoquest’s client base varies from primary care family doctors to medical specialists in tertiary hospitals across Malaysia. The company is also the one-stop referral centre for community laboratories, hospital laboratories, and even the public sector.

Company services are utilised by more than 4,000 doctors daily and around the clock, giving results to

Biochemistry Department: “The Roche total laboratory automation system has the capability to perform tests for over 10,000 patient episodes a day.”

over five million patient episodes each year.

Some of Innoquest’s achievements to date include being the first private laboratory in Malaysia to attain NATA and ISO 15189 accreditation. It is also the only multidisciplinary laboratory to achieve CAP accreditation in Malaysia, further enhancing the country’s reputation in quality service across the region. Innoquest directly manages over 65 private hospital labs, and a referral centre for an additional 200.

gap-up in the near future, including our foreign worker screening where Malaysia is still short of around one million foreign workers for our plantation, manufacturing, service and other key industries.

“We expect our borders to open soon for foreign workers to flood back. I am glad to see that our ministries are increasing the approvals of foreign workers; this will help our labour crunch tremendously. Health tourism will also experience higher traffic.

Innoquest continues to ensure all stakeholders mentioned receive

Pathology Department: “The recent pandemic has changed our perception on the importance of healthcare and diagnostics in general, and accelerated digitisation of the healthcare industry.”

the best diagnostic services, as our economy finds normalcy in the next few quarters.”

A FULL-SERVICE LAB PROVIDER PAH has recently set up a genomics lab under LifeStrands Genomics to complement existing competencies in Malaysia and the region. Within a short period, they have increased their NIPT (non-invasive prenatal testing) profiles and capacity, and have built a growing list of offerings including somatic oncology testing (with a highly competitive menu of comprehensive offerings),

pharmacogenomics testing, and have invested in liquid-based biopsy competency to be launched soon in Malaysia. Innoquest is proud to include LifeStrands services and products to its existing range of service offerings nationwide.

NIPT assesses a foetus’ risk of having certain chromosomal abnormalities including Down’s syndrome. A simple maternal blood test allows the laboratory to examine the foetal DNA - reducing the risk of complications such as miscarriage associated with more traditional methods of sampling and testing.

Healthcare Outlook Issue 1 | 9

INNOQUEST PATHOLOGY SDN BHD ASIA PACIFIC

“In Malaysia, the adoption of this test is still at a lower rate due to the prohibitive cost. However, PAH through our genomics lab and Innoquest Pathology offers a highquality NIPT service that is fully CAP accredited (the first of its kind in Malaysia),” Dr. Nheu continues. “Our task is to continue reducing the cost to make it affordable for pregnant women in Malaysia. I am proud to announce that our team is headed

by Dr. Vivek Rathi, one of the top molecular pathologists in Australia.

“We have also made strategic investments to launch various seamlessly interconnected platforms, allowing the doctor to order tests electronically, track the progress of all episodes, view lab results in real-time, have access to useful data such as their ordering pattern, their patient’s lab and other health records (for example, from their

wearables - smart watches, mobile phones and other devices).”

Innoquest continues to invest in other speciality testing competencies to complement its traditional lab services, such as animal pathology, and is the only private provider with a full menu for veterinarians, including microbiology and anatomical pathology lab services.

The company’s anatomical pathology services are complemented by a full range of immunohistochemistry testing and molecular testing for targeted therapy. Innoquest offers a comprehensive menu of toxicology testing backed by expertise based out of its sister laboratory in Australia called Safeworks Laboratories.

“I am also very excited about our plans in chemical and environmental testing, which will be revealed soon,” Dr. Nheu alludes.

Microbiology Department: “Innoquest Pathology is the first and only multidisciplinary laboratory to achieve CAP accreditation in Malaysia.”

10 | Healthcare Outlook Issue 1

AT THE CORE OF THE QUEST These plans and developments would falter without Innoquest’s hard-working staff, who remain the company’s heart and soul.

From the dedicated scientists working around the clock to the motorbike couriers who battle city traffic and all kinds of weather, Innoquest’s employees are working towards the goal of improving patient care. Innoquest emphasises standard operating procedures (SOPs) and strictly follows internal and external quality governance.

“From our recruitment policy towards fully qualified staff, followed by stringent training before they can operate independently, we foster professional and personal development to find the most adequate career path for each individual,” Dr. Nheu tells us.

Dr. Nelson Nheu and members of the Innoquest Pathology team, at the Inauguration Ceremony of the new brand name on 8th June 2022

“Having multiple labs with a range of specialties across the region gives our staff the opportunity for further development across functions, within and outside Malaysia (in our sister companies in Singapore, Philippines, Indonesia and Australia).”

Frequent assessments and appraisals are carried out at Innoquest to encourage regular feedback amongst staff and management, and to identify areas for improvement and growth. Company work culture focuses on teamwork and empathy, and on teaching and learning. Staff are rewarded for their excellence in performance, and we strongly encourage positive behaviour: great customer service to doctors and their patients is our central focus.

“In response to the growing awareness of mental wellbeing, especially during stressful times of the recent pandemic, we also engaged the services of an Employee Wellbeing consultant to ensure our employees’ concerns are seen to,” Dr. Nheu adds.

THE PATH AHEAD For Innoquest, a large part of the past three years revolved around managing the pandemic; the company was the first private laboratory in Malaysia to provide COVID-19 screening to the public and its efforts were mostly channelled to helping the public healthcare system conduct mass screening, as it was having difficulty coping with the large numbers at that time.

During these three years, Innoquest also expanded and built new labs to run COVID-19 tests across the country as well, and at the same time managed the pandemic within its own workforce.

“Today, as we ease into endemicity, we return our attention to our core laboratory testing, focusing on expanding our services to reach more people in the country, providing new test offerings to the community, selling tests from the personalised medicine field, histopathology, occupational health and safety,

and improving service delivery as a whole,” Dr. Nheu concludes. “In the coming years, we aim to provide a seamless patient journey through IT, from the ordering of tests by our doctors, to providing e-reports safely and efficiently through our IT platforms to improve patient care management and doctors’ experience.

“We continue to build our strong reputation in the medical and research field; growing and expanding partnerships with medical centres, other private and government institutions; we continue to drive improvements in patient care; staff competency, training and development.”

INNOQUEST PATHOLOGY SDN BHD Tel: +603 7841 7752 enquiries@innoquest.com.my www.innoquest.com.my Healthcare Outlook Issue 1 | 11

INNOQUEST PATHOLOGY SDN BHD HQ Office 2nd Floor, Wisma Tecna 18A, Jalan 51A/223 46100 Petaling Jaya Customer Careline: 1300 88 0234 International Call/ Emergency Backup Call: +603 7841 7752 enquiries@innoquest.com.my www.innoquest.com.my

PRODUCED BY HEALTHCARE OUTLOOK MAGAZINE